纳米体通过稳定部分开放的二维形状结构来抵消amyloidogenic光链的毒性
Luca Broggini1, Maria Monica Barzago2, Valentina Speranzini3
1Institute of Molecular and Translational Cardiology, IRCCS Policlinico San Donato, Piazza Malan 2, 20097 San Donato Milanese, Italy.
Journal of molecular biology
|October 21, 2023
概括
拉玛衍生的纳米体有效地中和与轻链氨基粉症 (AL) 相关的有毒可溶性轻链 (LCs). 这项研究揭示了一种新的LC结构,为AL氨基粉症提供了新的治疗点.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 轻链氨基粉症 (AL) 是一种全身性疾病,由错误折叠的免疫球蛋白轻链 (LC) 引起,导致严重的器官功能障碍和不良预后.
- 溶性LC物种的心脏毒性是AL氨基粉症的一个主要问题,但这些有毒物种的特征仍然很差.
- 目前针对AL氨基粉症的治疗策略需要新的方法来解决LC毒性.
研究的目的:
- 通过向可溶性有毒LC物种来确定AL粉样粉症的替代治疗策略.
- 描述特定LC变体所施加的心脏毒性机制.
- 开发用于氨基原性LCs的新型抑制剂.
主要方法:
- 从AL患者中产生针对心脏毒性LC (H3) 的五种拉玛衍生纳米体 (Nbs).
- 使用C. elegans in vivo模型,评估Nb在消除H3可溶性毒性的有效性.
- 对H3-Nb复合物的结构性表征,以阐明Nb作用机制.
主要成果:
- 开发的Nbs在 vivo中表现出在中和H3可溶性毒性的特异性和功效.
- 结构分析显示,Nbs与H3 VL域结合,稳定了一个独特的,部分开放的LC二极管.
- 这种稳定性防止VL域相互作用,表明抑制LC毒性和聚合的机制.
结论:
- 拉玛衍生纳米体是AL氨基粉症中可溶性LC毒性的强有力的抑制剂.
- 该研究发现了一种新的,部分开放的LC二元结构,为LC聚合和毒性机制提供了洞察力.
- 这些发现为开发针对AL氨基粉症的新治疗策略铺平了道路.
相关概念视频
03:03Amyloid Fibrils
9.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.6K
01:10Antibody Structure
60.2K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
60.2K
01:26Antibody Actions
1.1K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
1.1K
01:25Antibody Structure and Classes
931
Antibodies, also known as immunoglobulins, are produced by B cells in response to foreign substances, such as bacteria and viruses. These proteins are critical for recognizing and neutralizing these substances, protecting the body from potential harm.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
931